Hashimoto K, Prystowsky J H, Baird J, Lazarus G S, Jensen P J
Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia 19104.
J Invest Dermatol. 1988 Jun;90(6):823-8. doi: 10.1111/1523-1747.ep12462057.
Urokinase-type plasminogen activator (uPA) is produced and secreted by cultured human keratinocytes as a single chain precursor. UPA in keratinocyte conditioned medium is not susceptible to inhibition with diisopropylfluorophosphate (DFP), and it has an apparent molecular weight of 55 kD under both reducing and nonreducing conditions. Cleavage of keratinocyte uPA by plasmin results in the formation of a 96 kD complex comprised of activated uPA and PA inhibitor 2. PA extracted from normal human epidermis is only partially inhibited by DFP, suggesting that precursor uPA is also present in vivo. The synthesis of uPA as a precursor with reduced enzymatic activity as well as decreased affinity for inhibitors is likely to be a mechanism by which normal epidermis regulates plasminogen activation in vivo.
尿激酶型纤溶酶原激活剂(uPA)由培养的人角质形成细胞产生并作为单链前体分泌。角质形成细胞条件培养基中的uPA不易被二异丙基氟磷酸酯(DFP)抑制,并且在还原和非还原条件下其表观分子量均为55 kD。纤溶酶切割角质形成细胞uPA会导致形成由活化的uPA和PA抑制剂2组成的96 kD复合物。从正常人表皮中提取的PA仅被DFP部分抑制,这表明体内也存在前体uPA。以酶活性降低以及对抑制剂的亲和力降低的前体形式合成uPA可能是正常表皮在体内调节纤溶酶原激活的一种机制。